BerGenBio ASA

OB:BGBIO Stock Report

Market Cap: NOK 378.3m

BerGenBio Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Olav Hellebo

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21
We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13
It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11
We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21
What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

CEO

Olav Hellebo (59 yo)

less than a year

Tenure

Mr. Olav Hellebo, MBA, BBA, is Chief Executive Officer of BerGenBio ASA from November 21, 2024. He serves as Non-Executive Director of Antev Ltd. He is Director of Cytovation AS from July 2023.He serves o...

Leadership Team

NamePositionTenureCompensationOwnership
Rune Skeie
Chief Financial Officer6.8yrsNOK 3.59m0.010%
NOK 37.6k
Cristina Oliva
Chief Medical Officer2.8yrsNOK 5.70mno data
Olav Hellebo
Chief Executive Officerless than a yearno datano data
Graham Morell
Head of IRno datano datano data
Gayle Mills
Chief Business Officer3.2yrsNOK 3.39mno data
Akil Jackson
Medical Directorno datano datano data

3.0yrs

Average Tenure

59yo

Average Age

Experienced Management: BGBIO's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sally Bennett
Independent Non-Executive Director4.1yrsNOK 358.00k0.012%
NOK 45.7k
John Heymach
Member of Scientific Advisory Board1.9yrsno datano data
David Colpman
Non-Executive Directorless than a yearno datano data
Shu Kam Mok
Member of Scientific Advisory Board1.9yrsno datano data
Debra Barker
Independent Non-Executive Director5.8yrsNOK 344.00k0.012%
NOK 45.1k
Anders Tullgren
Independent Chairman of the Board3yrsNOK 848.00k0.055%
NOK 209.5k
Enriqueta Font
Member of Scientific Advisory Board1.9yrsno datano data
Solange Peters
Member Scientific Advisory Board1.9yrsno datano data

1.9yrs

Average Tenure

62yo

Average Age

Experienced Board: BGBIO's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:05
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BerGenBio ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Patrik LingDNB Markets
Geir HolomDNB Markets